Related Experiment Video
Updated: Oct 5, 2025
Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
CDK9 inhibitors in multiple myeloma: a review of progress and perspectives
Jędrzej Borowczak1, Krzysztof Szczerbowski2, Navid Ahmadi3
1Department of Clinical Pathomorphology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland. jedrzej.borowczak@gmail.com.
Abstract:
Currently, multiple myeloma is not yet considered a curable disease. Despite the recent advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 inhibitors emerged as a suitable agent to overcome resistance and prolong survival in patients with poor diagnoses. Downregulation of c-MYC, XIAP, Mcl-1 and restoration of p53 tumor-suppressive functions seems to play a key role in achieving clinical response. The applicability of the first generation of CDK9 inhibitors was limited due to relatively high toxicity, but the introduction of novel, highly selective drugs, seems to reduce the effects of off-target inhibition. CDK9 inhibitors were able to induce dose-dependent cytotoxicity in Doxorubicin-resistant, Lenalidomide-resistant and Bortezomib-resistant cell lines. They seem to be effective in cell lines with unfavorable prognostic factors, such as p53 deletion, t(4; 14) and t(14; 16). In preclinical trials, the application of CDK9 inhibitors led to tumor cells apoptosis, tumor growth inhibition and tumor mass reduction. Synergistic effects between CDK9 inhibitors and either Venetoclax, Bortezomib, Lenalidomide or Erlotinib have been proven and are awaiting verification in clinical trials. Although conclusions should be drawn with due care, obtained reports suggest that including CDK9 inhibitors into the current drug regimen may turn out to be beneficial, especially in poor prognosis patients.
Insights
Cyclin-dependent kinase 9 (CDK9) inhibitors show promise for treating multiple myeloma, especially in patients resistant to current therapies. These novel drugs induce cancer cell death and may improve survival rates in difficult-to-treat cases.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multiple myeloma remains largely incurable, with current therapies offering limited survival benefits for many patients.
- Therapeutic resistance is a significant challenge in multiple myeloma treatment, necessitating novel therapeutic strategies.
- Cyclin-dependent kinase 9 (CDK9) inhibitors represent a promising new class of drugs for overcoming treatment resistance.
Purpose of the Study:
- To evaluate the efficacy of CDK9 inhibitors in preclinical models of multiple myeloma.
- To investigate the mechanisms underlying the anti-myeloma activity of CDK9 inhibitors.
- To explore the potential of CDK9 inhibitors in overcoming resistance to established multiple myeloma therapies.
Main Methods:
- In vitro cytotoxicity assays using multiple myeloma cell lines, including those resistant to standard therapies (Doxorubicin, Lenalidomide, Bortezomib).
- Analysis of molecular targets, including c-MYC, XIAP, Mcl-1, and p53.
- Preclinical studies assessing tumor apoptosis, growth inhibition, and tumor mass reduction.
- Investigation of synergistic effects with other anti-myeloma agents.
Main Results:
- CDK9 inhibitors demonstrated dose-dependent cytotoxicity against drug-resistant multiple myeloma cell lines.
- These inhibitors were effective in cell lines with poor prognostic factors like p53 deletion and specific translocations.
- Preclinical trials showed induction of apoptosis, inhibition of tumor growth, and reduction in tumor mass.
- Synergistic effects were observed when CDK9 inhibitors were combined with Venetoclax, Bortezomib, Lenalidomide, or Erlotinib.
Conclusions:
- CDK9 inhibitors show significant potential as a novel therapeutic strategy for multiple myeloma.
- Their ability to overcome drug resistance and target unfavorable prognostic factors makes them particularly valuable.
- Further clinical trials are warranted to validate the efficacy and safety of CDK9 inhibitors in combination regimens for poor-prognosis patients.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers